Bilateral male breast cancer and prostate cancer: a case report.
(17/361)
Male breast cancer, consisting only 1% of all breast cancers, is occasionally associated with other primary malignancies, especially in patients with familial breast cancer history. Sporadic male breast cancers with another primary tumor are extremely rare. We report a 67-year-old male with asynchronous bilateral breast cancer and prostate cancer without familial breast cancer history. (+info)
Breast cancer before and during the AIDS epidemic in women and men: a study of Tanzanian Cancer Registry Data 1968 to 1996.
(18/361)
Kaposi's sarcoma and malignant lymphoma are two cancers that are most often associated with human immunodeficiency virus (HIV) infection. Recently, other cancers, including cervical cancer, have been associated with AIDS. The role of HIV in the pathogenesis of these malignancies is not well understood, and few studies have been done to determine any general increase in cancers after the onset of the HIV epidemic. This study compared breast cancer before and during the AIDS period by studying the total Tanzanian Cancer Registry data (1968 to 1996). The mean age among males increased from 50.88 to 52.63 years (p = 0.45) and among females decreased from 44.79 to 43.23 years (p = 0.005) before and during the AIDS epidemic, respectively. A statistically significant decrease in the incidence of breast cancer was observed during the AIDS epidemic period in both males (p = 0.001) and females (p = 0.021). The male-to-female ratio widened significantly from 0.09:1 to 0.03:1 (p = 0.0001). Further studies are needed to determine the incidence and observed changes of different cancers, including breast among patients with HIV/AIDS. (+info)
Oncogenes and male breast carcinoma: c-erbB-2 and p53 coexpression predicts a poor survival.
(19/361)
PURPOSE: To investigate the prognostic value of biomarkers in male breast carcinoma (MBC). PATIENTS AND METHODS: Fifty patients (mean age, 62.2 years) with invasive ductal carcinoma were retrospectively studied. All patients received surgery; 35 had adjuvant postoperative therapy. The median follow-up was 59 months (range, 1 to 230 months). c-myc, c-erbB-2, p53, and bcl-2 proteins were immunohistochemically detected on sections from formalin-fixed, paraffin-embedded tissues using 9E11, CB11, DO7, and bcl-2 124 monoclonal antibodies (mAbs). Estrogen, progesterone, and androgen receptors were detected using specific mAbs. Cell proliferation was assessed by MIB-1 mAb. RESULTS: In univariate analysis, c-myc, c-erbB-2, and p53 protein overexpression was significantly correlated with prognosis. The median survival was 107 months for c-myc-negative and 52 months for c-myc-positive patients (P =.01), 96 months for c-erbB-2-negative and 39 months for c-erbB-2-positive patients (P =.02), and 100 months for p53-negative and 33 months for p53-positive patients (P =.0008). Tumor histologic grade (P =.01), tumor size (P =.02), patient age at diagnosis (P =.03), and MIB-1 scores (P =.0004) also had prognostic value. In multivariate analysis, only c-erbB-2 and p53 immunoreactivity retained independent prognostic significance. All nine patients who did not express c-erbB-2 and p53 proteins were alive after 58 months, whereas none of the 14 patients expressing both proteins survived at 61 months follow-up (P =.0002). CONCLUSION: Overexpression of c-myc, c-erbB-2, and p53 proteins may be regarded as an additional prognostic factor in MBC. The combination of c-erbB-2 and p53 immunoreactivity can stratify patients into different risk groups. (+info)
Breast cancer risk in male twins: joint analyses of four twin cohorts in Denmark, Finland, Sweden and the United States.
(20/361)
To test the hypothesis that in utero exposure to high levels of oestrogen increases the risk of male breast cancer, we followed 115 235 male twins for more than 3.5 million person-years at risk. We observed 11 cases of male breast cancer versus 16.16 expected based on national rates (standardized rate ratio 0.68, 95% confidence interval 0.34-1.22) and conclude that any adverse influence of in utero oestrogen exposure is likely to be small. (+info)
Endocrine correlates of male breast cancer risk: a case-control study in Athens, Greece.
(21/361)
We studied the relation of certain endocrine-related variables among 23 cases of male breast cancer and 76 apparently healthy male controls. There were significant inverse associations with smoking (P = 0.03), birth order (P = 0.02) and reported frequency of orgasms in later life (P = 0.0004). The study provides strong indirect evidence that endocrine factors are important in the aetiology of male breast cancer. (+info)
Mammary adenocarcinoma in a male squirrel monkey (Saimiri sciureus).
(22/361)
A nodule was identified within the right mammary gland of a 16-year-old male squirrel monkey (Saimiri sciureus). The mass was excised and diagnosed as a mammary adenocarcinoma. The monkey developed congestive heart failure 1.5 years later and was euthanatized. At necropsy, a subcutaneous mass was found in the right axillary region. Histologically, the mass was identified as a lymph node whose architecture was effaced by neoplastic cells resembling those of the mammary tumor. Metastasis to internal organs was not observed. This is the first reported case of a mammary tumor in a New World primate and the only known case of mammary cancer in a male nonhuman primate. (+info)
Chemoprevention options for BRCA1 and BRCA2 mutation carriers.
(23/361)
BRCA1 and BRCA2 breast cancer predisposition gene mutation carriers are at markedly increased risk of breast and other cancers. The consideration of chemopreventative options will depend on the cancer site and age-specific penetrance curve. Most chemoprevention studies to date have investigated the role of endocrine intervention in women at increased risk of breast cancer, and study results are conflicting. At the present time, there is uncertainty regarding whether endocrine intervention, particularly with tamoxifen, is as effective in BRCA1 and BRCA2 mutation carriers as in other women who are at increased risk of breast cancer because of hormonal factors or genes with moderately conferred cancer risks. Furthermore, if chemoprevention were needed for at least 10 years to produce an effect, new chemoprevention agents will need to be developed for women in their 30s, as the breast cancer risk curves are steepest between 40 and 50 years of age. Consideration is now being given to types of chemoprevention in this younger age group. There is also an increased risk of other cancers (in particular ovarian cancer and, in men, prostate cancer), and considerations regarding chemoprevention will have to encompass cancer at these sites. (+info)
Clinical characteristics of Korean breast cancer patients in 1998. The Korean Breast Cancer Society.
(24/361)
The Korean Breast Cancer Society collected and formulated data for breast cancer in Korean through the nation-wide survey in 1998. The purposes of the present study were to determine the characteristics of breast cancer patients and compare these data with those from other countries. The data were collected from 36 university hospitals and 41 training hospitals. The total number of patients was 4,695. The estimated incidence of breast cancer in 1998 was 20.3 patients per 100,000 women. The median age was 47.0 years. The operation method was mastectomy (74.3%), breast conserving surgery (23.8%) and others (1.9%). The most prevalent stage was II (53.3%) followed by I (24.9%), III (13.7%), 0 (6.4%) and IV (1.7%). Other clinical and pathological findings were also evaluated. Several characteristics of breast cancer among Koreans tend to follow the patterns of western countries, and we need to understand the characteristics of Korean breast cancer through continuous investigations as the present study attempts. (+info)